

Jing Yuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6672495/publications.pdf>

Version: 2024-02-01

32
papers

8,596
citations

394421

19
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

20738
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 71, 2027-2034.	5.8	2,214
2	Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1582.	7.4	1,921
3	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. <i>Science China Life Sciences</i> , 2020, 63, 364-374.	4.9	1,606
4	Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 119-127.e4.	2.9	553
5	First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. <i>Infection</i> , 2020, 48, 773-777.	4.7	455
6	Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 71, 799-806.	5.8	395
7	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. <i>National Science Review</i> , 2020, 7, 1003-1011.	9.5	202
8	The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. <i>Inflammation Research</i> , 2020, 69, 599-606.	4.0	169
9	Laboratory Diagnosis and Monitoring the Viral Shedding of SARS-CoV-2 Infection. <i>Innovation(China)</i> , 2020, 1, 100061.	9.1	162
10	The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. <i>Structure</i> , 2020, 28, 1218-1224.e4.	3.3	140
11	Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 2230-2232.	5.8	132
12	Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test. <i>Annals of Translational Medicine</i> , 2020, 8, 1084-1084.	1.7	128
13	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	13.3	78
14	Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1708-1717.	4.0	72
15	Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. <i>Respiratory Research</i> , 2021, 22, 203.	3.6	64
16	Clinical and Immunological Characteristics of Human Infections With H5N6 Avian Influenza Virus. <i>Clinical Infectious Diseases</i> , 2019, 68, 1100-1109.	5.8	56
17	Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study. <i>Emerging Microbes and Infections</i> , 2020, 9, 2368-2378.	6.5	43
18	Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers. <i>Frontiers in Medicine</i> , 2021, 8, 595773.	2.6	42

#	ARTICLE	IF	CITATIONS
19	Saikosaponin C exerts anti-HBV effects by attenuating HNF1 α and HNF4 α expression to suppress HBV pgRNA synthesis. <i>Inflammation Research</i> , 2019, 68, 1025-1034.	4.0	23
20	The novel coronavirus (COVID-19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 317.	2.9	16
21	SARS-CoV-2 Detected on Environmental Fomites for Both Asymptomatic and Symptomatic Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 374-378.	5.6	12
22	Poly(I:C) Challenge Alters Brain Expression of Oligodendroglia-Related Genes of Adult Progeny in a Mouse Model of Maternal Immune Activation. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 115.	2.9	10
23	Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by <i>Acinetobacter Baumannii</i> : a case control study. <i>BMC Infectious Diseases</i> , 2018, 18, 664.	2.9	8
24	Structural insights into the inhibition of bacterial RecA by naphthalene polysulfonated compounds. <i>IScience</i> , 2021, 24, 101952.	4.1	6
25	Noninvasive Ventilation in Patients With COVID-19-Related Acute Hypoxemic Respiratory Failure: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 638201.	2.6	5
26	Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity. <i>Inflammation Research</i> , 2020, 69, 545-547.	4.0	4
27	Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013–2017. <i>Journal of Infection</i> , 2019, 79, 389-399.	3.3	3
28	Genetic and Phylogenetic Characterization of a Chikungunya Virus Imported into Shenzhen, China. <i>Virologica Sinica</i> , 2020, 35, 115-119.	3.0	3
29	Identification of a Novel Universal Potential Epitope on the Cytoplasmic Tail of H7N9 Virus Hemagglutinin. <i>Virologica Sinica</i> , 2019, 34, 334-337.	3.0	1
30	Reply to Lorentzen et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 2303-2304.	5.8	0
31	Geographic Differences on Clinical Manifestations of COVID-19 Infection Between Overseas Chinese and Local Chinese Patients. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2269-2277.	2.7	0
32	Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. <i>BMJ Open</i> , 2021, 11, e049104.	1.9	0